about
The Role of Copper Chaperone Atox1 in Coupling Redox Homeostasis to Intracellular Copper DistributionMetallothionein, Copper and Alpha-Synuclein in Alpha-Synucleinopathies.Proteome-wide analysis of neural stem cell differentiation to facilitate transition to cell replacement therapies.Insights on the interaction of alpha-synuclein and metals in the pathophysiology of Parkinson's disease.Redox- and non-redox-metal-induced formation of free radicals and their role in human disease.Effect of Disturbances of Zinc and Copper on the Physical and Mental Health Status of Patients with Alcohol Dependence.Insights into the human brain proteome: Disclosing the biological meaning of protein networks in cerebrospinal fluid.Coherent and Contradictory Facts, Feats and Fictions Associated with Metal Accumulation in Parkinson's Disease: Epicenter or Outcome, Yet a Demigod Question.Recent Advances in Macrocyclic Fluorescent Probes for Ion Sensing.Thiol-based copper handling by the copper chaperone Atox1.The Central Role of Biometals Maintains Oxidative Balance in the Context of Metabolic and Neurodegenerative Disorders.The Effect of the Human Peptide GHK on Gene Expression Relevant to Nervous System Function and Cognitive Decline.Oxidative modification of human ceruloplasmin induced by a catechol neurotoxin, salsolinolOccupational Metal Exposure and Parkinsonism.Subcellular Parkinson's Disease-Specific Alpha-Synuclein Species Show Altered Behavior in Neurodegeneration.Schizophrenia-risk and urban birth are associated with proteomic changes in neonatal dried blood spots.The Relevance of Iron in the Pathogenesis of Multiple System Atrophy: A Viewpoint.Phosphorylated α-Synuclein-Copper Complex Formation in the Pathogenesis of Parkinson's Disease.The dual enzyme LRRK2 hydrolyzes GTP in both its GTPase and kinase domains in vitro.Non-ceruloplasmin bound copper and ATP7B gene variants in Alzheimer's disease.Copper-64: a real theranostic agentParkinsonism in Inherited Metabolic Disorders: Key Considerations and Major FeaturesDifferential expression of miRNA 155 and miRNA 146a in Parkinson's disease patients
P2860
Q26740516-BA10D085-E414-49E1-BEED-0E96F4B52780Q37737068-5EB851D6-446E-4C5A-91FD-89C839CE8E73Q38264328-6BF66CD2-096F-44BC-B708-87757F763B94Q38343049-D842577D-2DCC-4EC1-B9D8-EB84BDDCE8BDQ38581859-F6698339-ED41-409B-A2CD-2E63D8A9C83DQ38628074-6EA472EA-95CE-4092-B6F2-383A1C7E8666Q38844925-FA882C8A-B2C8-4521-B135-1A7FC38DBAD9Q38915163-9B4F1EB5-6CB3-4C65-B68F-D88FD6D72409Q39104556-0FE78539-7CE8-418B-82EC-854001B49F81Q39179157-441930AF-AF74-4F44-AC45-E0F240D8244DQ41023080-029918F8-AF5A-49ED-BA47-690DDFEFE115Q42164137-ED36966D-3CBC-4177-BD85-FDB8D07DFC58Q42197717-1FE27F90-221A-4C1C-BBFF-EEBE2B796CD0Q46309593-FCE12445-7E22-4BF6-A19B-4C6F4054891DQ46460788-D6097C0E-EB5A-483E-B11D-4FC519F40FEAQ47241901-77155B04-2382-4950-BA74-A251D4624D18Q47835285-9878F123-A3E3-456A-9EB3-F16A87D2E6D8Q48246699-59A0D061-7254-4658-B581-2371E62EE746Q51275277-E76C6B39-79C5-48A0-9BD1-7AD32F3BC2C8Q51587028-72B46A98-250D-4313-AEDF-D4900054B962Q57484995-0356B2AB-1368-4297-833B-000C3D0E31E8Q58122613-C415F1BA-2E41-4739-9C53-AB7ECE2DADB2Q58740022-F677B0E1-5B7E-4966-BC71-7A091DAD1D0B
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Copper and copper proteins in Parkinson's disease.
@en
Copper and copper proteins in Parkinson's disease.
@nl
type
label
Copper and copper proteins in Parkinson's disease.
@en
Copper and copper proteins in Parkinson's disease.
@nl
prefLabel
Copper and copper proteins in Parkinson's disease.
@en
Copper and copper proteins in Parkinson's disease.
@nl
P2860
P50
P921
P356
P1476
Copper and copper proteins in Parkinson's disease.
@en
P2093
Camilo Rios
Luis Tristan-Lopez
P2860
P304
P356
10.1155/2014/147251
P5008
P577
2014-01-08T00:00:00Z